来宝网移动站

世联博研签约代理MaxCyte STX,MaxCyte GT,MaxCyte VLX,细胞转染系统,010-67529703

来宝网 2013/8/13点击3096次

 

MaxCyte STX®

Imagine a single transfection system that meets all your transfection needs. The MaxCyte STX® Scalable Transfection System uses next generation flow electroporation to cost-effectively produce the number and type of cells your research requires. The MaxCyte STX allows you to rapidly perform assay development, high throughput screening (HTS), high content screening (HCS), gram scale protein production, or an infinite number of other innovative applications. Explore the ways the MaxCyte STX can help open the doors to improving the quantity and quality of your drug candidates and biologics.

MaxCyte STX Scalable Transfection System
  • Fully scalable, able to transfect 5E5 cells in seconds up to 1E10 cells in < 30 minutes
  • Compatible with cell lines, primary cells, & difficult-to-transfect cell lines
  • Implement new expression systems and assays rapidly
  • Superior performance with reduced day-to-day assay variability
  • Computer controlled, plug–and-play system

MaxCyte STX Features

Simple:
 Pre-loaded with cell-type specific optimized protocols; plug and play transfection
Broad Range:
 Cell lines, primary cells, stem cells
Loading Agents:
 DNA, RNA, siRNA, proteins, small molecules
High Yield:
 >90% viability & recovery for many cell types
High Efficiency:
 >90% cell loading & transfection efficiency for many cell types
Scalable:
 5E5 cells to 4E7 using small-scale; up to 1E10 cells using large-scale flow electroporation
Rapid:
 5E5 cells in seconds; 1E10 cells in less than 30 minutes
HTS Compatible:
 Rapid, bulk transfections; able to cryopreserve transfected cells
Robust:
 Reproducible & consistent processing
Safe:
 Chemically defined media; sterile closed processing assemblies
Quality:
 cGMP compliant, ISO-certified, CE marked
 
  
Regulatory:
 Master File on record with USFDA

 

 

MaxCyte GT®

The MaxCyte GT® Transfection System is a cGMP-compliant, scalable therapeutic system with unparalleled consistency, scalability, and cell loading efficiency which is ideal for clinically-oriented cell modification. It enables the discovery, development and manufacturing of innovative therapeutic products for a wide range of diseases by overcoming the existing obstacles of cell therapy with its high-volume, rapid and inherently safe technology. The MaxCyte GT uses simple, computer-controlled protocols to transfect up to 1E10 cells in less than 30 minutes and is capable of loading multiple molecules (DNA, mRNA, siRNA, proteins, and small molecules) into autologous or allogenic immune, stem/progenitor or somatic cells. The system is pre-configured with protocols optimized for specific cell types and applications. This cell processing system has received Master File designation with the CBER Division of the U.S. FDA and has been cleared by NIH’s RAC and Health Canada.


MaxCyte GT Transfection System

  • Fully scalable, able to transfect 5E5 cells in seconds up to 1E10
    cells in < 30 minutes
  • CE marked platform for automated, robust, rapid, scalable, cGMPcompliant,
    closed processing for Cell Therapy Development
  • Obtain high viability and recovery of cells with augmented biological activity for
    development of more effective cellular therapeutics
  • Accelerate pre-clinical development and product evaluations in clinical trials by
    cross-referencing MaxCyte’s FDA Master File

     

Applications

  • Ex vivo Cell Therapy
  • Immunotherapy
  • Regenerative Medicine
  • Viral Vector Manufacturing

MaxCyte GT Features

Simple:
 Ease and flexibility of use
High Yield:
 >90% viability & recovery for many cell types
High Efficiency:
 >90% cell loading & transfection efficiency for many cell types
Scalable:
 5E5 cells in seconds; up to 1E10 cells in less than 30 minutes
Safe:
 Chemically defined media (no added ’biologicals’)
Rugged:
 Reproducible processing
Quality:
 cGMP compliant, sterile closed system
Regulatory:
 Master File on record with FDA, CE marked

MaxCyte VLX®

The MaxCyte VLX® Large Scale Transfection System is a small-footprint, easy-to-use instrument specifically designed for extremely large volume transient transfection. Using proprietary flow electroporation technology, the MaxCyte VLX can transfect up to 2E11 cells in less than 30 minutes with high cell viability and transfection efficiencies. This cGMP-compliant system is ideal for the rapid production of recombinant proteins, monoclonal antibodies, viral vectors, vaccines & VLPs from the bench through cGMP pilots and commercial manufacturing.

The MaxCyte VLX Allows Scientists to:

  • Produce multi-gram scale quantities of proteins and antibodies
  • Protein production from R&D through large scale cGMP applications
  • Transiently transfect up to 2E11 cells in < 30 minutes
  • Reduce the reliance on stable cell lines
  • Shorten the timeline for development of proteins and antibodies

What if you could produce grams of protein without constructing a single stable cell line?

The MaxCyte VLX Large Scale Transfection System can transiently transfect up to 2E11 cells in a single 30 minute transfection run. Optimized electroporation protocols designed specifically to maximize protein expression enable multi-gram level production from even historically difficult-to-transfect cells such as CHO cells. The MaxCyte VLX uniquely meets the speed, reproducibility and safety needed for manufacturing of human therapeutics and makes protein production via transient transfection a viable alternative to the development of stable cell lines.

Plasmid
eGFP
EPO-IRES-eGFP
Volume of Cells
380 mL
1 L
Number of Cells
3.8 x 1010
2.2 x 1010
Cell Viability
95%
97%
eGFP+
82%
-
EPO Production
(IU/106 cells)
-
17

High-quality Transfection using the MaxCyte VLX. Cells grown in a 25L WAVE Bioreactor™ were harvested, washed and resuspended in MaxCyte electroporation buffer. Cells were transfected via flow electroporation using the MaxCyte VLX at the designated volumes with either an eGFP or EPO-IRES-eGFP expression vector. Cell viability, GFP expression and erythropoietin (EPO) production were assessed.
推荐仪器
  • *
  • *
  • *
  • *